JPRN-UMIN000001347已完成未知
A clinical phase I study to define recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone(C-BD) for relapsed and refractory multiple myeloma - A phase I study of combination with cyclophosphamide, bortezomib and dexamethasone for relapsed and refractory multiple myeloma
Center for Supporting Hematology-Oncology Trial(C-SHOT)0 个研究点目标入组 18 人开始时间: 2008年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria includes; 1.Cardiovascular diseases 1) Angina pectoris, and acute myocardial infarction within recent 6 months 2) congestive heart failure which requires treatment 3) arrhythmia which requires treatment 2. Respiratory diseases 1) interstitial pneumonitis 2)COPD 3)infections more than twice which in a previous year 3. infectious diseases 1) HIV infection 2) HBsAg positive 3) HBsAb and/or HBcAb posive 4) anti HCV positive 4. neuropathy 1) peripheral neuropathy grade>= 2 2) neural pain due to peripheral neuropaty 5. diabetes mellitus 6. allergy to cyclophosphamide 7.active double cancer 8.subjects who are not likely to participate in the study for any reason in the opinion of the investigator
研究者
相似试验
进行中（未招募）
1 期
Phase II Clinical Trial to optimize the dose of an anti-NKG2A monoclonal antibody (humZ270 mAb, IPH2201) for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing haploidentical transplantation with posttransplantation cyclophosphamide.Patients with acute myeloid leukemia or myelodysplastic syndrome undergoing haploidentical transplantation with posttransplantation cyclophosphamide.MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005902-24-ITIRCCS ISTITUTO CLINICO HUMANITAS42
已完成
不适用
Phase I study to optimize the safe starting dose of weekly paclitaxelhead and neck cancerJPRN-UMIN000020357Kanazawa University24
尚未招募
不适用
A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson’s diseaseDiseases of the nervous systemKCT0004536Medihelpline188
尚未招募
1 期
Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to CarfilzomibCancerACTRN12621001458820South Western Sydney Local Health District36
已完成
不适用
STUDY PHASE I / II DETERMINATION OF THE DOSAGE, PHARMACOKINETICS AND SECURITY OF EPIRUBUBIN (ELLENCE TM / PHARMORRUBICINA TM FARMORRUBICINA TM) IN PEDIATRIC ONCOLOGICAL PATIENTS WITH REFRACTORY OR RECURRENT DISEASE, WITH EVALUATION OF EFFECTIVENESS IN PATIENTS WITH NEUROBLASTOMA, STS AND BONE SARCOMA, REFRACTORY.PER-106-03PHARMACIA & UPJOHN INTERAMERICAN CORPORATION SUCURSAL DEL PERU,